Intuitive Surgical Inc

Intuitive Surgical Inc(ISRG)股票分析

$452.290

+8.594 (+1.90%)收盤時

Loading chart…
最高
458.450
開盤
443.650
成交量加權均價
451.10
成交量
3.01M
市值
157.88B
最低
442.560
成交金額
1.36B
企業價值/稅息折舊攤銷前利潤(TTM)
44.54

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.

AI 分析 of Intuitive Surgical Inc (ISRG)

買進

Intuitive Surgical Inc is a good buy right now due to its recent earnings beat with an EPS of $2.53, exceeding estimates by 18.78%, and a forward P/E ratio of 33.33, indicating growth potential at a reasonable valuation. The stock has shown a positive momentum with a 5-day change of +6.00% and a current RSI of 76.78, suggesting strong buying interest. However, the main risk is the recent 10% drop in share price following disappointing earnings, which could indicate market volatility ahead.

分析師評級(17)

上檔空間 +40.91%
買進
11 買進
5 持有
1 賣出
目前: 452.29
最低
575.00
平均
637.32
最高
740.00

BTIG

2026-10-12

目標價

$454

買進

Barclays

2026-10-06

目標價

$485

增持

Oppenheimer

2026-08-12

目標價

—

優於大盤

HSBC

2026-07-30

目標價

$391

持有

UBS

2026-07-28

目標價

$500

買進

估值指標

Intuitive Surgical Inc(ISRG)目前預期本益比為 33.33,5 年平均預期本益比為 53.97。

預期本益比

低估
5 年均值 P/E
53.97
目前P/E
33.33
高估
64.65
低估
43.29

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
37.04
目前EV/EBITDA
44.54
高估
44.30
低估
29.78

預期股價營收比

低估
5 年均值 P/S
15.40
目前P/S
11.78
高估
18.70
低估
12.09

Alphio AI 對 ISRG 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ISRG

$605.58

情境價格

基

基準

基準 · 50%ISRG

$559.78

情境價格

悲

悲觀

悲觀 · 25%ISRG

$542.00

情境價格

持有 ISRG 的大戶

L

Lingotto Investment Management LLP

+ 持有ISRG

+19.92%

3個月報酬率

P

Peregrine Capital Management, LLC

+ 持有ISRG

+13.32%

3個月報酬率

M

Millennium Management LLC

+ 持有ISRG

+10.94%

3個月報酬率

H

Hyperion Asset Management Limited

+ 持有ISRG

+10.34%

3個月報酬率

L

LGT Fund Management Company AG

+ 持有ISRG

+9.63%

3個月報酬率

C

Campbell & Company, LP

+ 持有ISRG

+9.56%

3個月報酬率

事件時間軸

2026-10-21 (ET)

09:00:00

Stock Futures Rise as Brent Crude Surpasses $110

2026-10-20 (ET)

20:00:00

Treasury Yields Retreat as Netflix Falls Over 5%

17:30:00

Company Sees Continued Segmentation in Q3 Customer Base

17:00:00

da Vinci Surgical Robot Reaches $450M Settlement

16:30:00

Q3 Revenue Reaches $3.05B, Exceeding Consensus

資訊

ISRG 常見問題 —— 由 Alphio AI 解答

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Intuitive Surgical Inc is a good buy right now due to its recent earnings beat with an EPS of $2.53, exceeding estimates by 18.78%, and a forward P/E ratio of 33.33, indicating growth potential at a reasonable valuation. The stock has shown a positive momentum with a 5-day change of +6.00% and a current RSI of 76.78, suggesting strong buying interest. However, the main risk is the recent 10% drop in share price following disappointing earnings, which could indicate market volatility ahead.

17 analysts cover ISRG: 11 rate it Buy, 5 Hold and 1 Sell. The average price target is 637.32.

ShortOutpost5 天前

$ISRG "Trade Idea 2: Buy the October 23 Expiry 437.50/452.50 Call Spread ($6.60) and sell the October 23 Expiry 410 Put for 30 cents." The call spread looks to be a bust; may need to roll puts down and out.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易